Navigation Links
Study Suggests Invega Helps Patients With Schizophrenia Maintain,,,Symptom Control

52-Week Trial Maintained Improvement in Personal and Social Performance

COLORADO SPRINGS, Colo., March 30, 2007 /PRNewswire/ -- Longer-term treatment with INVEGA(TM) (paliperidone) Extended-Release Tablets, a new once daily oral medication for schizophrenia, helped many patients effectively control their symptoms and maintain their improvements in personal and social functioning.

These latest data are from a large, open label, international clinical trial sponsored by Janssen, L.P., the U.S. marketer of INVEGA, and were presented today at the International Congress on Schizophrenia Research (ICOSR). INVEGA was approved last December by the U.S. Food and Drug Administration for the treatment of schizophrenia.

"Schizophrenia imposes serious, lifelong psychological, physical, social, and economic burdens on patients, caregivers and heath care systems worldwide," said Herb Meltzer, MD, Bixler/May/Johnson Professor of Psychiatry & Pharmacology at the Vanderbilt University School of Medicine. "I am encouraged by the results of this pooled analysis because of the need for antipsychotic treatment options that provide effective symptom control, good tolerability, and which help to sustain the ability of patients to function over the long term."

In a pre-planned analysis, researchers evaluated data from 1,083 patients at 168 centers across North America, Europe, Asia, South Africa, and 12 other countries in the open-label extension (OLE) of three similarly designed six- week double-blind studies. In the 52-week OLE phase of the studies, the patients maintained effective symptom control and the improvement in personal and social performance achieved during the six-week double-blind phase.

These studies provided longer-term follow-up to the three previously completed six-week, placebo-controlled trials that demonstrated efficacy and
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:7/10/2014)... , July 10, 2014  The U.S. Department ... three-year grant to University Hospitals (UH) Case Medical Center ... new national model aimed at improving care for patients ... Care," the project will test a unique model developed ... with late-stage disease, significant comorbidities, or demonstrated need for ...
(Date:7/10/2014)... AMBLER, Pa. , July 10, 2014 /PRNewswire/ ... visited Moberg Research,s (Moberg) medical device manufacturing facility. ... how Moberg,s advanced neurological monitors facilitate cutting-edge research ... 2011, Rep. Kennedy and mental health advocate, ... non-profit organization dedicated to fostering fundamental changes that ...
(Date:7/10/2014)...  Decision Resources Group finds that while more ... are willing to prescribe Durata,s Dalvance (dalbavancin) and ... OPAT, approximately two-thirds of the respondents reported a ... inpatients. However, our findings indicate that nearly two-thirds ... OPAT following hospital discharge, and most are discharged ...
Breaking Medicine Technology:University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4Representative Patrick Kennedy visits Moberg's medical device facility to discuss improvement in brain injury care 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3
... ... ... ... ...
... ... ... ... , , ...
Cached Medicine Technology:Microfluidics International Corporation Announces Fourth Quarter and Year-End 2009 Financial Results 2Microfluidics International Corporation Announces Fourth Quarter and Year-End 2009 Financial Results 3Microfluidics International Corporation Announces Fourth Quarter and Year-End 2009 Financial Results 4Microfluidics International Corporation Announces Fourth Quarter and Year-End 2009 Financial Results 5Microfluidics International Corporation Announces Fourth Quarter and Year-End 2009 Financial Results 6Microfluidics International Corporation Announces Fourth Quarter and Year-End 2009 Financial Results 7Microfluidics International Corporation Announces Fourth Quarter and Year-End 2009 Financial Results 8Microfluidics International Corporation Announces Fourth Quarter and Year-End 2009 Financial Results 9Microfluidics International Corporation Announces Fourth Quarter and Year-End 2009 Financial Results 10Microfluidics International Corporation Announces Fourth Quarter and Year-End 2009 Financial Results 11Microfluidics International Corporation Announces Fourth Quarter and Year-End 2009 Financial Results 12Microfluidics International Corporation Announces Fourth Quarter and Year-End 2009 Financial Results 13Chimerix CEO George Painter, Ph.D., to Speak on Improving Biodefense Product Discovery and Development Strategies at Institute of Medicine Workshop 2Chimerix CEO George Painter, Ph.D., to Speak on Improving Biodefense Product Discovery and Development Strategies at Institute of Medicine Workshop 3
(Date:7/10/2014)... According to a new market research report ... Naval), Application (Software Defined Radios, SATCOM, Encryption, Smartphones, ... Asia-Pacific, Europe, the Middle East & ROW) - ... market is estimated to be $30.15 billion in ... of 5.56% to reach $39.52 billion by 2019 ...
(Date:7/10/2014)... A Forever Recovery , an open-ended ... to a great start and gives them a solid ... a new Eating Disorders section of its website at ... , Different types of eating disorders listed ... (DSM-IV), including anorexia nervosa, bulimia nervosa, and EDNOS (Eating ...
(Date:7/10/2014)... electronic health record becomes widespread across the United States, ... Care Act, the quantity of clinical data that will ... dramatically increase. Additionally, experts in healthcare have become ... of data for the purpose of gleaning insights that ... care a process that is known as big ...
(Date:7/10/2014)... Teens who are sensitive to light or noise after ... such as anxiety and depression, a new study says. ... issues teens experience after concussion may help in planning ... when to return to play and what accommodations are ... Koehl and Dong Han, of the University of Kentucky ...
(Date:7/10/2014)... Dennis Thompson HealthDay Reporter ... out of 10 adults make use of calorie information on ... restaurants, according to a new U.S. study. Women in ... Seung Hee Lee-Kwan, an epidemiologist with the U.S. Centers for ... said they used menu labeling to help choose their meal, ...
Breaking Medicine News(10 mins):Health News:Portable Communication Systems Market Projected to Reach $39.52 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Portable Communication Systems Market Projected to Reach $39.52 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Portable Communication Systems Market Projected to Reach $39.52 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Latest A Forever Recovery Launches Eating Disorders Section on Website 2Health News:Six cases where big data can reduce healthcare costs 2Health News:Six cases where big data can reduce healthcare costs 3Health News:Six cases where big data can reduce healthcare costs 4Health News:Some Teens May Face Emotional Problems After Concussion 2Health News:60 Percent of Diners Use Calorie Labeling When Posted: CDC 2Health News:60 Percent of Diners Use Calorie Labeling When Posted: CDC 3
... Institute, a,leading healthcare career training provider, has announced John ... company,s board of directors.,Hopkins, currently the company,s chief executive ... during the board,s Feb. 4th meeting. , ... The consolidation of leadership roles ...
... (OTC Bulletin Board: MLSS), the recognized leader in advanced ... at the upcoming Chicago Dental Society,s 144th Midwinter Meeting ... sales of the STA Single Tooth Anesthesia System ... with four successive quarters of sales growth in 2008, ...
... babies and parents through the worst of teethingTHOUSAND OAKS, ... relief for their children, the options have been limited ... retailers who sell baby products have a groundbreaking therapeutic ... desperately seeking relief for their babies. The technology behind ...
... Provides Additional Free Resources to support Customer,s Weight ... leading provider of weight management products and services, ... with improved usability, new information architecture and visual ... that supports NutriSystem customers and new dieters to ...
... Physicians in Particular, According to New Report from ... a leading provider of managed care market intelligence, ... a number of challenges in the coming year, ... the new Orange County Market Overview , ...
... performing western blots -- a popular analytical technique used to ... ... CT (Vocus) February 23, 2009 -- Carestream Molecular Imaging, a ... for performing western blots -- a popular analytical ...
Cached Medicine News:Health News:MedVance Institute Promotes John L. Hopkins to Chairman of the Board of Directors 2Health News:Milestone Scientific to Exhibit at the Chicago Dental Society's 144th Midwinter Meeting 2Health News:Milestone Scientific to Exhibit at the Chicago Dental Society's 144th Midwinter Meeting 3Health News:Milestone Scientific to Exhibit at the Chicago Dental Society's 144th Midwinter Meeting 4Health News:Groundbreaking JeJe Teether Vibrates Pain Safely Away 2Health News:Groundbreaking JeJe Teether Vibrates Pain Safely Away 3Health News:NutriSystem.com Gets a Complete Makeover 2Health News:NutriSystem.com Gets a Complete Makeover 3Health News:NutriSystem.com Gets a Complete Makeover 4Health News:Regulations Against Balance Billing to Impact Orange County, Calif., Physicians' Bottom Line 2Health News:Carestream Molecular Imaging Releases Western Blot Kits For Added Convenience, Better Performance 2Health News:Carestream Molecular Imaging Releases Western Blot Kits For Added Convenience, Better Performance 3
Premium Full Color Digital Ultrasound...
... The new ACUSON CV70 cardiovascular ultrasound ... capabilities in a powerful, all-digital ultrasound ... sensitivity, color flow sensitivity and spatial ... the ACUSON family of cardiovascular products. ...
Aplio was designed for intuitive operation so you can get the results you are looking for quickly and easily. From customizable measurement packages to an ergonomic platform design, Aplio was built m...
AngioSpeed V series, it is an Angiography system designed for vascular treatment in various radiological regions, cardiology, and neurology. SHIMADZU brings you a single system with all units fused t...
Medicine Products: